Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | GYS1 | P13807 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663779 | 0.90 | FFAR1 (0.42) | VSIRPRMT6EPHX2KDM4CFFAR1 | |
| SCHEMBL4152914 | 0.87 | PRMT6 (0.43) | VSIRPRMT6EPHX2KDM4CPDCD1 | |
| SCHEMBL3668234 | 0.84 | FFAR1 (0.37) | KDM4CFFAR1FFAR4NR4A2 | |
| SCHEMBL3724410 | 0.83 | FFAR1 (0.48) | FFAR1FFAR4 | |
| SCHEMBL3730365 | 0.83 | GRIN2D (0.47) | PRMT6EPHX2 | |
| SCHEMBL3666546 | 0.82 | PRMT6 (0.48) | VSIRPRMT6EPHX2PDCD1CD274 | |
| SCHEMBL3664072 | 0.80 | SCN8A (0.46) | VSIRPRMT6EPHX2PDCD1CD274 | |
| SCHEMBL3724194 | 0.80 | PRMT6 (0.66) | PRMT6EPHX2KDM4CSCN8A | |
| SCHEMBL4173616 | 0.79 | PRMT6 (0.42) | PRMT6KDM4CFFAR1AOC3 | |
| SCHEMBL13778407 | 0.79 | VSIR (0.49) | VSIRPRMT6EPHX2KDM4CFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101970435-B | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2014-07-02 | — | — | CN | claimed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | claimed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | VSIR 3811/4885PRMT6 1956/4885EPHX2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.